3.64
-0.01 (-0.27%)
| Penutupan Terdahulu | 3.65 |
| Jumlah Dagangan | 799,902 |
| Harga / Jualan (P/S) | 124.49 |
| Harga / Buku (P/B) | 12.80 |
| Julat 52 Minggu |
| Margin Operasi (TTM) | -384.43% |
| EPS Cair (TTM) | -3.63 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -29.90% |
| Nisbah Semasa (MRQ) | 0.920 |
| Aliran Tunai Operasi (OCF TTM) | -85.93 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -56.25 M |
| Pulangan Atas Aset (ROA TTM) | -63.60% |
| Pulangan Atas Ekuiti (ROE TTM) | -1,642.75% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Inventiva S.A. - American Depos | Bercampur | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 0.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 0.9 |
| Purata Bergerak Teknikal | -1.0 |
| Osilator Teknikal | 2.0 |
| Penilaian Relatif | NA |
| Kesihatan Kewangan | -4.7 |
| Persekitaran Makro | -2.8 |
| AI Insight | NA |
| AI Technical | NA |
| Purata | -0.59 |
|
Inventiva SA is a France-based clinical-stage biopharmaceutical company focused on the development of oral small-molecule therapies for the treatment of MASH. The wholly-owned research and development facility and a team with expertise and experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation. Leveraging the expertise, the company is also advancing lanifibranor for the treatment of MASH and has a pipeline of earlier-stage therapeutic programs in oncology. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Institusi | 5.09% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Symbiosis Capital Partners, Llc | 31 Mar 2026 | 2,354,000 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |